- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00109499
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
An Open-label, Phase I, Single Administration, Dose- Escalation Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
The primary purpose of this study is to assess the safety of AdGVPEDF.11D when given to patients with "wet" age-related macular degeneration (AMD). AdGVPEDF.11D is a replication deficient (E1, E3 and E4 deleted) adenovirus vector containing the gene for the PEDF (pigment epithelium-derived factor) protein. PEDF is a protein that naturally exists in the human eye, but whose levels are altered in diseases characterized by ocular neovascularization like AMD. The PEDF protein is known to have anti-angiogenic effects or, in other words, it has the ability to inhibit growth of new blood vessels.
AdGVPEDF.11D will be delivered once via intravitreal injection into one eye. The injected eye will be the eye with the worst visual acuity.
Study Overview
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Retina-Vitreous Associates Medical Group
-
Los Angeles, California, United States, 90033-4682
- Retinal Transplantation Laboratory
-
Los Angeles, California, United States, 90095-7000
- UCLA - Jules Stein Eye Research Center
-
-
Florida
-
Boynton Beach, Florida, United States, 33426
- Florida Eye Microsurgical Institute, Inc.
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital School of Medicine
-
-
Michigan
-
Detroit, Michigan, United States, 48201-1423
- Kresge Eye Institute
-
-
Oregon
-
Portland, Oregon, United States, 97201
- Casey Eye Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than or equal to 50 years;
- Severe neovascular AMD in at least one eye responsible for a best corrected vision of 20/200 or worse in the study eye (if both eyes have neovascular AMD and equal visual acuity scores, the study eye will be determined by the investigator);
- Best corrected visual acuity in the fellow eye must be equal to or better than the study eye;
- Fluorescein angiography of the study eye must show evidence of a leaking subfoveal choroidal neovascular lesion. The subfoveal component must consist of CNV (choroidal neovascularization), blood or fibrosis. The total size of the lesion must be ≤12 MPS disc areas. The presence of a leaking subfoveal choroidal neovascular lesion will be evaluated by the investigator at the clinical site to determine patients' eligibility.
- Must not be candidates for (including patients who have had treatment with either modality in the past and are no longer candidates) or must have refused treatment with subfoveal laser photocoagulation or PDT (photodynamic therapy);
- Informed consent;
- Able to comply with protocol requirements including follow-up visits.
Exclusion Criteria:
- Liver enzymes > 2 x ULN (ALT, AST, bilirubin);
- Clinical evidence of active infection of any type, including adenovirus, hepatitis A, B, or C virus or HIV virus;
- Other treatment for AMD in the study eye within the last twelve weeks prior to Day 1;
- Other experimental medications within the last four weeks prior to Day 1;
- Significant retinal disease other than neovascular AMD, such as diabetic retinopathy or retinal vascular occlusion;
- Significant non-retinal disease such as ocular atrophy;
- Cataract or other significant media opacity that might compromise examination and photography of the posterior segment;
- Other causes of choroidal neovascularization such as pathologic myopia ( > 8 diopters), ocular histoplasmosis or angioid streaks;
- Evidence of inflammation (grade 1 or higher) in the anterior and/or posterior chambers;
- Cataract surgery or submacular surgery within 3 months;
- Prior ocular treatment with radiation;
- Known allergy to fluorescein;
- Abnormal prothrombin or partial thromboplastin time ( > 1.5 X ULN) or anticoagulant therapy that cannot be withheld for treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GV-003.001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
University of Modena and Reggio EmiliaCompletedMacular Degeneration Advanced | Macular Degeneration, Dry | Macular Degeneration, Senile | Macular Scar | Macular Degeneration NonexudativeItaly
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Clinical Trials on AdGVPEDF.11D
-
GenVecNational Institutes of Health (NIH)UnknownLocally Advanced Prostate CancerUnited States